Latest News and Press Releases

SEATTLE, WA--(Marketwired - Sep 12, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced it will be a featured presenter at the Rodman & Renshaw 18th Annual Global Investment...

SEATTLE, WA--(Marketwired - Aug 31, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS), today announced the pricing of an underwritten public offering of 1,150,000 shares of its common stock at a price...

SEATTLE, WA--(Marketwired - Aug 30, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The...

SEATTLE, WA--(Marketwired - Aug 25, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced a reverse split of its common stock at a ratio of 1-for-15, effective August 26, 2016, and that the...

SEATTLE, WA--(Marketwired - Aug 12, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced Second Quarter ended June 30, 2016 financial results and provided an update on recent company...

SEATTLE, WA--(Marketwired - Aug 10, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) announced today that it will provide a Company update and discuss second quarter 2016 financial results on Monday,...

SEATTLE, WA--(Marketwired - Aug 5, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) and Besins Healthcare Luxembourg SARL ("Besins") have agreed, pursuant to a Termination Agreement dated August 4,...

SEATTLE, WA--(Marketwired - Jun 7, 2016) -  Atossa Genetics Inc. (NASDAQ: ATOS) today announced that it has initiated a new drug development program with oral endoxifen. Endoxifen is an active...

SEATTLE, WA--(Marketwired - May 27, 2016) - Atossa Genetics, Inc. (NASDAQ: ATOS) today announced that it has entered into a $10 million stock purchase agreement with Aspire Capital Fund, LLC. Under...

SEATTLE, WA--(Marketwired - May 5, 2016) - Atossa Genetics Inc. (NASDAQ: ATOS) today announced First Quarter ended March 31, 2016 financial results and provided an update on recent company...